Literature DB >> 26667601

The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.

R Ball1, M Robb1, S A Anderson2, G Dal Pan1.   

Abstract

In May 2008, the Department of Health and Human Services announced the launch of the Sentinel Initiative by the US Food and Drug Administration (FDA) to create the Sentinel System, a national electronic system for medical product safety surveillance. This system complements existing FDA surveillance capabilities that track adverse events reported after the use of FDA regulated products by allowing the FDA to proactively assess the safety of these products. Published 2016. This article is a US Government work and is in the public domain in the USA.

Entities:  

Mesh:

Year:  2016        PMID: 26667601     DOI: 10.1002/cpt.320

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  64 in total

1.  Carrying out streamlined routine data analyses with reports for observational studies: introduction to a series of generic SAS ® macros.

Authors:  Yuan Liu; Dana C Nickleach; Chao Zhang; Jeffrey M Switchenko; Jeanne Kowalski
Journal:  F1000Res       Date:  2018-12-19

2.  A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool.

Authors:  Rachel E Sobel; William Blackwell; David M Fram; Andrew Bate
Journal:  Drug Saf       Date:  2019-11       Impact factor: 5.606

3.  Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate 'Real World' Evidence of Comparative Effectiveness and Safety.

Authors:  Shirley V Wang; Olga V Patterson; Joshua J Gagne; Jeffrey S Brown; Robert Ball; Pall Jonsson; Adam Wright; Li Zhou; Wim Goettsch; Andrew Bate
Journal:  Drug Saf       Date:  2019-11       Impact factor: 5.606

Review 4.  Big Data Science: Opportunities and Challenges to Address Minority Health and Health Disparities in the 21st Century.

Authors:  Xinzhi Zhang; Eliseo J Pérez-Stable; Philip E Bourne; Emmanuel Peprah; O Kenrik Duru; Nancy Breen; David Berrigan; Fred Wood; James S Jackson; David W S Wong; Joshua Denny
Journal:  Ethn Dis       Date:  2017-04-20       Impact factor: 1.847

Review 5.  Efficient design of clinical trials and epidemiological research: is it possible?

Authors:  Michael S Lauer; David Gordon; Gina Wei; Gail Pearson
Journal:  Nat Rev Cardiol       Date:  2017-04-27       Impact factor: 32.419

6.  Real World Evidence: Time for a Switch?

Authors:  Rachel E Sobel; Andrew Bate; Robert F Reynolds
Journal:  Drug Saf       Date:  2018-12       Impact factor: 5.606

7.  Prediction of Cardiovascular Risk to Guide Primary Prevention.

Authors:  Gregory D Curfman
Journal:  JAMA Intern Med       Date:  2018-09-01       Impact factor: 21.873

8.  Use of FDA's Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure.

Authors:  Efe Eworuke; Emily C Welch; Anne Tobenkin; Judith C Maro
Journal:  Drug Saf       Date:  2019-07       Impact factor: 5.606

9.  Pharmacoepidemiology in the era of real-world evidence.

Authors:  Sengwee Toh
Journal:  Curr Epidemiol Rep       Date:  2017-10-19

10.  Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database.

Authors:  Jie Li; Genna Panucci; David Moeny; Wei Liu; Judith C Maro; Sengwee Toh; Ting-Ying Huang
Journal:  JAMA Intern Med       Date:  2018-11-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.